ATE488501T1 - Cyclopropylpiperidinglycin-transporter-inhibito - Google Patents

Cyclopropylpiperidinglycin-transporter-inhibito

Info

Publication number
ATE488501T1
ATE488501T1 AT05801197T AT05801197T ATE488501T1 AT E488501 T1 ATE488501 T1 AT E488501T1 AT 05801197 T AT05801197 T AT 05801197T AT 05801197 T AT05801197 T AT 05801197T AT E488501 T1 ATE488501 T1 AT E488501T1
Authority
AT
Austria
Prior art keywords
cyclopropylpiperidinglycine
inhibito
transporter
glycine transporter
transporter glyt1
Prior art date
Application number
AT05801197T
Other languages
English (en)
Inventor
Craig Lindsley
David Wisnoski
Scott Wolkenberg
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE488501T1 publication Critical patent/ATE488501T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05801197T 2004-09-30 2005-09-26 Cyclopropylpiperidinglycin-transporter-inhibito ATE488501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61494204P 2004-09-30 2004-09-30
PCT/US2005/034301 WO2006039221A2 (en) 2004-09-30 2005-09-26 Cyclopropyl piperidine glycine transporter inhibitors

Publications (1)

Publication Number Publication Date
ATE488501T1 true ATE488501T1 (de) 2010-12-15

Family

ID=36142986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05801197T ATE488501T1 (de) 2004-09-30 2005-09-26 Cyclopropylpiperidinglycin-transporter-inhibito

Country Status (16)

Country Link
US (1) US7776886B2 (de)
EP (1) EP1797035B1 (de)
JP (1) JP4646984B2 (de)
KR (1) KR20070058565A (de)
CN (1) CN101031547A (de)
AT (1) ATE488501T1 (de)
AU (1) AU2005292323B2 (de)
BR (1) BRPI0515954A (de)
CA (1) CA2581582C (de)
DE (1) DE602005024838D1 (de)
IL (1) IL182253A0 (de)
MX (1) MX2007003816A (de)
NO (1) NO20072208L (de)
RU (1) RU2387644C2 (de)
WO (1) WO2006039221A2 (de)
ZA (1) ZA200701612B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105902A1 (en) * 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
US7576083B2 (en) * 2004-05-05 2009-08-18 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
WO2006067529A1 (en) * 2004-12-21 2006-06-29 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as glyt1 inhibitors
AU2006256583B2 (en) * 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
US8163956B2 (en) 2005-06-13 2012-04-24 Merck Sharp & Dohme Corp. Inhibitors of GLYT1 transporters
CA2627177A1 (en) 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors
WO2010102003A2 (en) * 2009-03-03 2010-09-10 Vanderbilt University Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
EP3134406A1 (de) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituierte 2,4,5,6-tetrahydropyrrolo [ 3,4-c ] pyrazol-und 4,5,6,7-tetrahydro-2 h-pyrazolo [ 4,3-c ] pyridinverbindungen als glyt1-inhibitoren
TWI601712B (zh) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6458790B2 (en) * 2000-03-23 2002-10-01 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7071213B2 (en) * 2001-11-14 2006-07-04 Schering Corporation Cannabinoid receptor ligands
GB0130696D0 (en) 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20070105902A1 (en) * 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
US7576083B2 (en) * 2004-05-05 2009-08-18 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
WO2006067529A1 (en) * 2004-12-21 2006-06-29 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as glyt1 inhibitors
AU2006256583B2 (en) * 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
US7834031B2 (en) 2005-09-29 2010-11-16 Merck Sharp & Dohme Corp. Radiolabeled glycine transporter inhibitors
CA2627177A1 (en) 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors

Also Published As

Publication number Publication date
WO2006039221A2 (en) 2006-04-13
WO2006039221A3 (en) 2006-09-08
US7776886B2 (en) 2010-08-17
JP4646984B2 (ja) 2011-03-09
IL182253A0 (en) 2007-09-20
ZA200701612B (en) 2009-05-27
KR20070058565A (ko) 2007-06-08
US20080108663A1 (en) 2008-05-08
AU2005292323B2 (en) 2011-06-09
AU2005292323A1 (en) 2006-04-13
BRPI0515954A (pt) 2008-08-12
JP2008514705A (ja) 2008-05-08
CN101031547A (zh) 2007-09-05
CA2581582A1 (en) 2006-04-13
EP1797035B1 (de) 2010-11-17
EP1797035A2 (de) 2007-06-20
EP1797035A4 (de) 2009-08-05
NO20072208L (no) 2007-04-27
RU2387644C2 (ru) 2010-04-27
RU2007116165A (ru) 2008-11-10
MX2007003816A (es) 2007-04-24
DE602005024838D1 (en) 2010-12-30
CA2581582C (en) 2010-07-20

Similar Documents

Publication Publication Date Title
ATE488501T1 (de) Cyclopropylpiperidinglycin-transporter-inhibito
WO2005046601A3 (en) 4-phenyl piperdine sulfonyl glycine transporter inhibitors
WO2007053400A3 (en) Piperidine glycine transporter inhibitors
WO2005094514A3 (en) Heteroaryl piperidine glycine transporter inhibitors
DE602005025941D1 (de) Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen
WO2005107469A3 (en) Morpholinyl piperidine glycine transporter inhibitors
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
DE602007008434D1 (de) Rezeptoren
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
CY1106902T1 (el) Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
EA200702109A1 (ru) Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
EP1814535A4 (de) Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
TW200724140A (en) Hydantoin compounds
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties